Pentwater Capital Management’s ALX Oncology ALXO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-12,898
Closed -$953K 209
2021
Q3
$953K Sell
12,898
-102
-0.8% -$6.8K 0.01% 193
2021
Q2
$711K Buy
13,000
+3,000
+30% +$180K 0.01% 229
2021
Q1
$737K Buy
10,000
+2,000
+25% +$157K 0.01% 249
2020
Q4
$690K Sell
8,000
-11,900
-60% -$716K 0.01% 183
2020
Q3
$751K Buy
+19,900
New +$782K 0.01% 174

Other funds holding ALXO

Pentwater Capital Management's ALXO Position: Q4 2021 in Review

Pentwater Capital Management sold out of ALX Oncology (ALXO) in Q4 2021, closing a stake of 12,898 shares — an estimated $953K sold.

Pentwater Capital Management first reported a position in ALXO in Q3 2020 and held it in 5 quarters. The position peaked at $953K in Q3 2021. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

  • Pentwater Capital Management reported no remaining ALX Oncology position as of Q4 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 12,898 ALX Oncology shares in Q4 2021, an estimated $953K.
  • Pentwater Capital Management first reported a position in ALX Oncology in Q3 2020 and held it in 5 quarters.
  • Pentwater Capital Management's ALX Oncology position peaked at $953K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on Pentwater Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.